Fluorinated Integrin Antagonists for Topical Retinal Angiogenesis Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME) face challenges due to poor ocular pharmacokinetics, toxicity concerns, and the complexity of administration, particularly with systemic and intravitreal injection methods.
Innovation Solution
Development of novel fluorinated compounds that act as αv integrin antagonists, specifically targeting αvβ3 and αvβ5 integrins, allowing for topical administration to treat or prevent these conditions by inhibiting angiogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic or intravitreal injection methods are used to administer anti-angiogenic drugs, then therapeutic efficacy is improved, but treatment complexity and invasiveness increase
Solution Approach 1:
The patent replaces invasive mechanical injection methods with non-invasive topical eye drop administration. The fluorinated integrin antagonist compounds are delivered through ocular surface application, eliminating needles and syringes while maintaining therapeutic effectiveness against neovascularization in AMD and DR
Solution Approach 2:
The patent uses fluorinated compounds as intermediary agents that bridge the gap between topical application and deep retinal target engagement. These compounds serve as mediators that can penetrate ocular tissues and reach integrin receptors on endothelial cells without requiring direct injection into the vitreous or systemic circulation
2Ease of operation
If existing integrin antagonists are administered topically, then administration simplicity is improved, but ocular pharmacokinetics and tissue penetration are insufficient
Solution Approach 1:
The patent applies fluorine substitution at specific positions on the integrin antagonist core structure to fundamentally change the compound's physicochemical parameters. This fluorination enhances lipophilicity, metabolic stability, and ocular tissue penetration, enabling these compounds to achieve therapeutic concentrations in the retina and choroid after topical application
Solution Approach 2:
The patent creates composite molecular structures by combining the integrin-binding RGD motif with fluorinated aromatic rings and linker groups. This composite design maintains high affinity for αvβ3 and αvβ5 integrins while incorporating fluorinated moieties that improve ocular pharmacokinetics and tissue distribution
3Reliability
If current anti-angiogenic treatments are used, then neovascularization inhibition is achieved, but toxicity concerns arise from excipients and carriers
Solution Approach 1:
The patent extracts and eliminates harmful excipients and carriers from the treatment system. By using small molecule fluorinated compounds that can be administered as simple eye drops, the formulation removes toxic components such as benzalkonium chloride and mannitol that are present in peptide-based integrin antagonists, while maintaining anti-angiogenic efficacy
Data Source
AI summary
The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.